SIX-listed Santhera Pharmaceuticals has signed an exclusive licensing agreement with biopharma company Nxera Pharma for the development, manufacturing and commercialisation across Japan, South Korea, Australia and New Zealand of Agamree, a prescription medicine used to
Homburger advised Santhera in connection with its CHF 20 m royalty monetization and convertible bond financing. The deal encompassed an USD 13 m royalty monetization financing with R-Bridge, an affiliate of Singapore-based healthcare-focused investment firm CBC Group.
Homburger advised Santhera Pharmaceuticals on its entrance into a royalty monetization financing totaling up to USD 38 m with R-Bridge, an affiliate of CBC Group, amongst Asia’s largest healthcare-focused investment firms. Santhera is monetizing 75% of
Legalcommunity.ch
Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).
For further information, please visit the Group’s website www.lcpublishinggroup.com
